The 15mg+ extreme tier, and who should avoid it

There is no regulated tier at 15 mg and above — “extreme” is a marketing boundary, not a legal one. Only two brands publish per-pouch figures that high on their own sites, the loudest strong brands publish no figure at all, and I could not find a single jurisdiction that permits a 15 mg pouch as an ordinary consumer product.

The strength ladder on this site stops making sense somewhere above the 9–11 mg tier. Below that, the numbers are mostly comparable: two authorised American manufacturers publish per-pouch milligrams, the products are reviewed, and the figures have been measured by third parties. Above it, three things happen at once. The denominator changes without warning, the evidence that more nicotine means more nicotine delivered runs out, and the brands with the most aggressive claims stop publishing numbers altogether.

So this page is not a ranking of the strongest pouches. It is an account of what is actually documented at this tier, what is not, and who the published risk assessments say should stay away from it.

What actually exists above 15 mg a pouch

I looked for products where the manufacturer’s own website publishes a nicotine figure of 15 mg or more per pouch. Retailer listings and review sites do not count, because the figure is the whole claim and a reseller is free to invent it.

Two brands qualify.

Pablo, made by N.G.P Tobacco ApS of Denmark, is the cleanest published spec at this tier and the only one that gives you everything you need to check it. Its 24MG range lists “Nicotine in pouch:24mg”, “Nicotine:30 mg/g”, “Pouch weight:0.8g” and “Net weight: 16g” with 20 pouches a can. The 20MG range reads 20 mg a pouch at 25 mg/g, same 0.8 g pouch. Both are internally consistent: 0.8 g at 30 mg/g is 24 mg. The ladder runs 3, 6, 9, 13, 20 and 24 mg, and 24 mg is the ceiling — Pablo publishes nothing above it.

Nordic Spirit Max, from Gallaher Limited, is the other, and it is a worked example of why this tier is confusing. The UK FAQ gives Max as “Standard pouch size: 17mg per pouch / 24mg of nicotine per gram”. The Swedish FAQ gives the same tier as “Max – Standardpåse: 16,8 mg per påse / 24 mg nikotin per gram”, and publishes the pouch mass: 0.7 g. Only the Swedish set is arithmetically honest — 0.7 g at 24 mg/g is exactly 16.8 mg, and the same holds down the Swedish ladder (10.5, 8.4, 5.6 mg). The UK figures imply a pouch of 0.708 g for Max and 0.647 g for X-Strong, which cannot both describe the same product. My reading is that the UK numbers are rounded up for the shelf. The brand also states the problem itself, on the Swedish page: “Våra dosor visar antingen milligram (mg) nikotin per påse eller mg nikotin per gram” — our cans show either milligrams per pouch or milligrams per gram.

That is the list. Outside those two, I could not find a brand owner publishing a per-pouch figure at or above 15 mg anywhere.

The genuinely extreme numbers are published per gram, not per pouch

The figures people actually mean by “extreme” — 50 mg, 75 mg, 100 mg — are real, and they are not per pouch. FEDRS, a Polish manufacturer, runs two catalogues side by side: a “Regulated Portfolio” at “5–20 mg/g” and a “High-Strength Portfolio” described on its homepage as “50–100 mg/g” and “built for markets without strict mg/g limits”. Every high-strength item is tagged “NON-REGULATED MARKETS”, and the buyers named are “Distributors operating in non-regulated markets”. The company says its products are “manufactured in Poland, inside the EU” — and Poland’s own legal cap is 20 mg/g.

Two things about that are worth stating plainly. First, the company cannot keep its own ceiling straight: the homepage says “50–100 mg/g” in one sentence and “50–75 mg/g” in the next, one product card reads “50 / 65 / 100 mg/g” and the high-strength page says “50 / 65 / 75 mg/g”. Second, and more usefully, FEDRS publishes no per-pouch figure and no pouch mass anywhere on its site. I searched for both. So nobody reading the manufacturer’s own data can work out what a dose is.

If you want an estimate, you have to borrow a mass from somewhere else, and then it is arithmetic rather than a published figure. Germany’s Federal Institute for Risk Assessment measured a median pouch weight of 0.6 g; at that mass, 50 mg/g is about 30 mg a pouch and 100 mg/g about 60 mg. Using Pablo’s published 0.8 g instead gives 40 mg and 80 mg. Those are my calculations from two unrelated sources, and the manufacturer neither publishes nor endorses them.

The brands with the biggest reputations publish nothing at all

This is the finding that surprised me most, and it is a set of clean negatives rather than a claim.

Swedish Smokeless, which owns Siberia, White Fox, HIT and Oden’s, publishes no milligram figure for any product on any page I could read. Siberia is described only as “ranging from ‘normal’ to ‘extremely strong'” and as having a strength “up to 5 times higher than other conventional snus brands”. The widely quoted “43 mg/g” for Siberia appears on retail sites, not on the manufacturer’s.
Killa is made by the same company as Pablo, which publishes exhaustive specs for Pablo — and gives Killa no nicotine figure of any kind.
Loop, Skruf, Zone and X All White publish no milligram figure on their own sites either.
VELO’s Swedish site tops out at 14 mg, below this tier, and states every figure as a bare “Styrka: 14MG” with no basis at all.

Put against the measurement literature, that matters. Rantaša and Finšgar found pouch nicotine content generally lower than declared, averaging −28.8% with one product 52.9% out. But a declared value is the thing being checked. The brands making the loudest strength claims declare nothing, so there is no label to test and no way for a buyer to be wrong about it in either direction.

Where a 15 mg pouch can legally be sold

Almost nowhere, and the reason is more interesting than the conclusion: the caps are written on two different denominators, so a per-gram limit does not forbid a strong pouch, it forbids a concentrated one.

Jurisdiction	Limit	Basis	A 15 mg pouch?
United States	11 mg is the authorised ceiling	per pouch	No — nothing above 11 mg is authorised
Latvia	4 mg/g	per gram	No, at any plausible mass
Canada	4 mg	per dosage unit	No — above it, a prescription drug
Denmark	9.0 mg	per pouch	No
Czechia	12 mg per dose, 240 mg per pack	per dose	No, twice over
Finland	16.6 mg/g, pouch mass 0.5–1.0 g	per gram + mass band	Only at 0.904 g or heavier
Iceland	20 mg/g	per gram	Only at 0.75 g or heavier
Poland	20 mg/g	per gram	Only at 0.75 g or heavier
Netherlands, Belgium	total ban	—	No
Germany	no cap; category withdrawn as a novel food	—	No — and nor is a 3 mg pouch
Norway	pre-approval; nothing approved	—	No
Sweden, United Kingdom	none in force	—	Yes

The hardest cap I could verify is Latvia’s 4 mg per gram, in the law on the circulation of tobacco products and tobacco substitute products, article 3, paragraph 5.¹: “maksimālā nikotīna koncentrācija tabakas aizstājējproduktā nepārsniedz četrus miligramus uz gramu”. It has been in force since 1 January 2025, manufacturers challenged it, and the Constitutional Court upheld it on 24 October 2025 — “Spriedums ir galīgs un nepārsūdzams”, the judgment is final and unappealable. At 4 mg/g a one-gram pouch may hold 4 mg, so Latvia rules out not just this tier but most of the European mainstream.

Iceland’s regulation 992/2022, article 6, is as blunt as drafting gets: “Einungis er heimilt að selja nikótínvörur sem innihalda að hámarki 20 mg/g af nikótíni” — only nicotine products containing at most 20 mg/g may be sold. Note that Iceland has two “20” figures, 20 mg/ml for e-liquid in its Act and 20 mg/g for nicotine products in this regulation; secondary sources conflate them.

Canada did something different again. Since 14 January 2026 its Prescription Drug List exempts nicotine only “in the form of a buccal pouch containing 4 milligrams or less of nicotine per dosage unit”; above that, Health Canada’s notice says, “it would be considered a prescription drug”. There is no authorised prescription nicotine pouch, so in Canada a 15 mg pouch is not a capped consumer product — it is a drug nobody may dispense.

Run the two best-documented products through that table and you get the point. Pablo 24MG fails Denmark on dose, Czechia on both dose and pack total (24 mg × 20 pouches is 480 mg against a 240 mg cap), Poland, Iceland, Finland and Latvia on concentration, the United States on authorisation and Canada on drug status, and is banned outright in the Netherlands, Belgium, Germany and Norway. Nordic Spirit Max fails the same list and is lawful on the two home markets where it is actually sold. Meanwhile Pablo’s own 13MG — below this tier — passes Finland, Poland and Iceland on concentration at 16.25 mg/g and fails Denmark and Czechia on dose. A per-pouch cap and a per-gram cap sort the same product differently, and “15 mg” is not a boundary in either system.

Does a bigger number deliver more nicotine?

Between 15 and 24 mg, there is no published evidence that it does, and there is direct regulator-funded evidence that the relationship breaks down.

The ceiling of the pharmacokinetic literature is 30 mg a pouch, in a study run by Germany’s Federal Institute for Risk Assessment (BfR) with LMU Munich. Participants held nicotine-free, 6 mg, 20 mg and 30 mg pouches for 20 minutes. After the 30 mg pouch “the peak concentration in blood was 29.3 ng/ml, higher than after smoking a cigarette (15.1 ng/ml)” — but the institute’s own conclusion is the sentence that matters: “No linear correlation was found between the nicotine content in the pouch and the nicotine concentration in the blood.” Its explanation is that the products came from different manufacturers, so “variations in the percentage and rate of nicotine release are possible”. The same opinion records two products from different makers, each containing 10 mg, producing peak concentrations of 11.9 and 17.1 ng/ml. That is a 44% spread at an identical label.

The published analysis of that trial, by Mallock-Ohnesorg and colleagues, puts it as findings that “speak against a linear relationship between nicotine delivery and nicotine content in the pouch”, with relative bioavailability of 70% for the 20 mg pouch and 165% for the 30 mg against the 6 mg. It was funded by BfR’s own intermural funding, grant BfR-CPS-08-60-0102-02.P606, with no commercial relationships declared — which is worth noting, because most pouch pharmacokinetics is paid for by manufacturers.

A 2025 crossover from the Wolfson Institute at Queen Mary University of London, funded from internal funds with no competing interests declared, reaches the same place from below: a single 9 mg pouch produced a higher peak than the participants’ own cigarettes (27.9 vs 19.5 ng/ml), and the authors describe “nicotine delivery not always corresponding with pouch strength”.

So the honest summary is narrow and it is worth being exact about. One jump is documented — somewhere above 20 mg, early absorption starts to resemble a cigarette’s. Within the commercial “extreme” range, brand-to-brand release differences are larger than the differences between the numbers on the cans, and nothing has been measured at all on the 50–100 mg/g products. There is no pharmacokinetic study of them in the literature I can reach.

The skull-and-crossbones question

You will see it claimed that pouches above 16.7 mg/g must carry the GHS06 skull-and-crossbones pictogram. The BfR opinion is the source, and it says both things.

Section 3.1.1, reporting a cited survey, states that labels “for products with a nicotine content of 2.5 mg/g or higher must bear the GHS07 pictogram (exclamation mark, signal word: ‘Warning’) while those exceeding 16.7 mg/g must bear pictogram GHS06 (skull and crossbones, signal word: ‘Danger’)”. Section 3.1.4 derives the same 16.7 mg/g from the CLP mixture formula — “(100 × 5)/300 = 1.67%” — and then says the opposite: “For nicotine pouches, this would represent a concentration of 16.7 mg per g of pouch leading to a classification in hazard category 4 under chemicals legislation. In this category, labelling with the skull and crossbones pictogram is not required.”

Both sentences are in one document. My reading is that 16.7 mg/g is the boundary between acute oral toxicity categories 3 and 4, so it is the concentration at which a mixture stops being category 4 and starts being category 3 — which is why one passage treats it as the trigger and the other as the top of the safer band. The underlying figure is not in dispute: the European Chemicals Agency’s risk assessment committee proposed classifying nicotine as Acute Tox. 2 (oral) with the hazard statement “H300: Fatal if swallowed” and an acute toxicity estimate of 5 mg/kg bodyweight, and BfR notes this “has now been taken up into law with the adoption of EU Regulation 2018/1480”.

What I would not do is treat a pictogram threshold as a verdict on a pouch. It is a labelling rule for chemical mixtures, derived from a dose in milligrams per kilogram of bodyweight, and it tells you about concentration rather than about what happens in a mouth for 30 minutes.

Who should avoid it

The published risk assessments name groups, and none of them makes the list conditional on strength. BfR’s is the clearest: “In terms of effects on health, the BfR defines the following high-risk groups: Children, adolescents and non-smokers, as nicotine is an addictive substance. Pregnant and breastfeeding women, because of the effects of nicotine during pregnancy and its passage into breast milk. People with cardiovascular disease, as nicotine has strong cardiovascular effects.”

Read that list against the arithmetic of this tier and the children’s point stops being abstract. The US Food and Drug Administration, urging manufacturers to use child-resistant packaging in September 2025, reported that “Approximately 72% of nicotine pouch exposure cases occurred in children under 5 years of age” and that “Toxic effects in young children have been reported with nicotine doses as low as 1 to 4 milligrams”. A single Pablo 24MG pouch contains 24 mg. A 0.6 g pouch at 100 mg/g would contain about 60 mg.

For adults, the picture is less dramatic than the folklore and still not reassuring. The canonical “60 mg kills an adult” figure was traced back by Bernd Mayer in Archives of Toxicology to “dubious self-experiments” in the nineteenth century; his revised estimate is that “the lower limit causing fatal outcomes is 0.5–1 g of ingested nicotine”, an oral LD50 of “6.5–13 mg/kg”. That work was supported by the Austrian Science Fund rather than industry, and I should say that the article page carries no competing-interests statement. The revision cuts both ways: it retires the two-pouches-could-kill-you framing, and 0.5 g of nicotine is still twenty-odd of the strongest pouches on sale. BfR’s own poisoning committee recorded a case in which “a pouch with 20 mg nicotine had been swallowed” and the person “did not develop any symptoms other than stomach pain”.

The sharpest evidence is about adolescents, and it carries a gap worth naming. A 2026 case report in Cureus describes two serum-confirmed poisonings in Epirus, Greece — “a 15-year-old boy and a 13-year-old girl” — with nicotine levels of 134 ng/ml and 266 ng/ml; the girl lost consciousness within 20 minutes of use. The authors’ framing is the one I would borrow: “The distinction between ‘reduced harm’ and ‘risk-free’ is crucial.” They declared no financial support and no financial relationships. And here is the gap: I searched the full text and it gives no brand, no strength and no number of pouches. Two hospital admissions with laboratory confirmation, and the product specification is simply absent from the clinical record. The same is true at scale — the large US poison-centre work reporting a steep rise in pouch ingestions among small children does not capture milligram strength either. As far as I can establish, no poison-centre dataset separates high-strength pouches from weak ones, which means the one question this page exists to ask has never been studied epidemiologically.

None of this is a reason to treat the mainstream tiers as safe. BfR’s view of the whole category is that if the acute reference dose it proposes is applied, “nicotine pouches containing all nicotine quantities presented in this report will be withdrawn from the market” — and a 6 mg pouch already produced a significant heart-rate rise in its own study. The 15 mg+ tier is the far end of a category-wide problem, not a separate one.

Two countries make the number mean something

If the complaint on this page is that a milligram figure without a denominator is useless, two jurisdictions have fixed it by law.

Czechia’s decree 141/2023 requires on the pack “obsah nikotinu v mg na jednu dávku nikotinového sáčku” — nicotine content in milligrams per single dose — along with the number of doses, and caps a dose at 12 mg (“Jedna dávka nikotinového sáčku může obsahovat maximálně 12 mg nikotinu”) and a pack at 240 mg with at least 20 doses. Three numbers, one denominator, and they reconcile exactly.

Latvia goes further and is the only jurisdiction I found that requires both halves of the fraction: the nicotine amount per packet and per pouch, and the mass of product per packet. Declare the mass and the dose and a per-gram cap stops being gameable — which is presumably why the country with the strictest cap is also the one that asks for both numbers.

Frequently asked questions

Is there a 50 mg nicotine pouch?

There are pouches sold at 50 mg per gram, which is not the same claim. At the median measured pouch weight of 0.6 g that is roughly 30 mg per pouch, but that is my arithmetic — the manufacturer selling at 50–100 mg/g publishes no pouch mass at all, so its per-pouch dose cannot be derived from its own data.

Why can I buy these online if they are illegal almost everywhere?

Because the cap binds the seller in the market where the sale happens, and manufacturers segment their catalogues around it — one of them openly labels a product line “NON-REGULATED MARKETS”. Whether a parcel into your country is lawful depends on your own jurisdiction’s rules on distance selling and importation, which differ from its content cap and are covered on the country pages here.

Does a stronger pouch hit faster?

Not reliably. The only documented step change is above 20 mg, and in the one regulator-funded trial two different makers’ 10 mg pouches produced peak blood levels 44% apart. Release rate is set by the pouch design and formulation, not just the dose.

Is 15 mg too strong for a first pouch?

Every published risk assessment I have read puts non-smokers in its highest-risk group, at any strength, and the authorised American ceiling for anyone is 11 mg. If you are new to nicotine, this tier is the wrong end of the ladder entirely — see choosing your first strength.

Which countries still allow this tier?

Of those I could verify to a primary instrument, Sweden and the United Kingdom have no content cap in force. The UK has a statutory power to set one that has not been used.

Sources

Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches, Opinion 023/2022 — high-risk groups, the 16.7 mg/g derivation and the GHS passages, the 1.79–47.5 mg sampled range, median 0.6 g and 9.48 mg per pouch, the BfR/LMU 6–30 mg trial, the swallowed-pouch case.
US Food and Drug Administration, Nicotine pouch products authorized by the FDA — 43 products, two companies, 11 mg ceiling, content current 21 August 2026.
US Food and Drug Administration, FDA urges nicotine pouch manufacturers to use child-resistant packaging, 2 September 2025.
Latvia, law on the circulation of tobacco products, tobacco substitute products, herbal smoking products, electronic smoking devices and their liquids, article 3 paragraph 5.¹ (4 mg/g, in force 1 January 2025; labelling duties), and Constitutional Court case 2024-16-01, judgment of 24 October 2025.
Iceland, Reglugerð nr. 992/2022, article 6 (20 mg/g), under Lög nr. 87/2018 article 8.
Czechia, Vyhláška č. 141/2023 Sb., §§ 2(4), 2(5) and 4(4)(b).
Health Canada, Notice of amendment: revisions to the Prescription Drug List for nicotine buccal pouches, 14 January 2026.
Mallock-Ohnesorg N. et al., Frontiers in Pharmacology 15:1392027 (2024) — funded by BfR intermural funding, grant BfR-CPS-08-60-0102-02.P606, no commercial relationships declared.
Przulj D. et al., “Nicotine delivery from and user reactions to nicotine pouches compared to cigarettes”, Psychopharmacology (2025), doi 10.1007/s00213-025-06961-1 — funded from internal funds, no competing interests declared.
Mayer B., “How much nicotine kills a human?”, Archives of Toxicology 88:5–7 (2014) — Austrian Science Fund P24005 and P24946; no competing-interests statement on the article page.
Gketsi V. et al., “Acute nicotine poisoning from nicotine pouch use in adolescents”, Cureus 18(2):e103698 (2026) — no financial support declared.
Rantaša M. and Finšgar M., Analyst (2026), doi 10.1039/d6an00153j — Slovenian Research Agency and ERDF; no conflict of interest declared.
Manufacturer specifications read on 11 October 2026: Pablo 24MG and 20MG and 13MG; Nordic Spirit UK FAQ and Nordic Spirit Sweden FAQ; FEDRS high-strength markets; Swedish Smokeless brands; N.G.P. Tobacco on Killa.

Last verified 11 October 2026.